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ABSTRACT
Objectives: To determine the feasibility of a
randomised controlled trial of ‘leave on’ emollients for
children with eczema.
Design: Single-centre, pragmatic, 4-arm, observer-
blinded, parallel, randomised feasibility trial.
Setting: General practices in the UK.
Participants: Children with eczema aged 1 month to
<5 years.
Outcome measures: Primary outcome—proportion
of parents who reported use of the allocated study
emollient every day for the duration of follow-up
(12 weeks). Other feasibility outcomes—participant
recruitment and retention, data collection and
completeness and blinding of observers to
allocation.
Interventions: Aveeno lotion, Diprobase cream,
Doublebase gel, Hydromol ointment.
Results: 197 children were recruited—107 by self-
referral (mainly via practice mail-outs) and 90 by
inconsultation (clinician consenting and randomising)
pathways. Participants recruited inconsultation were
younger, had more severe Patient-Oriented Eczema
Measure scores and were more likely to withdraw than
self-referrals. Parents of 20 (10%) of all the
randomised participants reported using the allocated
emollient daily for 84 days. The use of other non-study
emollients was common. Completeness of data
collected by parent-held daily diaries and at monthly
study visits was good. Daily diaries were liked (81%)
but mainly completed on paper rather than via
electronic (‘app’) form. Major costs drivers were
general practitioner consultations and eczema-related
prescriptions. Observer unblinding was infrequent, and
occurred at the baseline or first follow-up visit through
accidental disclosure.
Conclusions: It is feasible in a primary care setting to
recruit and randomise young children with eczema to
emollients, follow them up and collect relevant trial
data, while keeping observers blinded to their
allocation. However, reported use of emollients (study
and others) has design implications for future trials.
Trial registration number: ISRCTN21828118/
EudraCT2013-003001-26.
INTRODUCTION
Eczema (also referred to as atopic dermatitis
or atopic eczema) affects around 20% of
children in the UK. Incidence peaks in the
ﬁrst 2 years of life and decreases thereafter.1
It is characterised by dry and itchy skin, and
it can have a signiﬁcant impact on the
quality of a child’s life and their family.2
In countries with strong systems of primary
care, such as the UK, the majority of
children with eczema are diagnosed and
managed by their family physician or general
practitioner (GP) with emollients and topical
Strengths and limitations of this study
▪ This pragmatic study demonstrates that it is feas-
ible to recruit children with eczema from primary
care, randomise them to a ‘leave on’ emollient
and follow them up for 12 weeks with good
observer blinding.
▪ Participant retention was better in participants
who referred themselves into the study com-
pared with those who were recruited during con-
sultations with their general practitioner or
practice nurse, although they also differed in
respect of their age and parent-reported eczema
severity.
▪ While it was possible to collect daily, weekly and
monthly outcome data, missing data in parent-
completed diaries have made interpretation of
adherence to allocation challenging.
▪ There were practical and technical limitations
with the ‘app’ version of the parent-completed
diary.
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corticosteroids. Emollients are recommended for the
majority of patients and they are primarily used as a ‘leave
on’ treatment to reduce eczema symptoms. Applied dir-
ectly to the skin, emollients reduce water loss by occlusion
and/or directly adding water to the dry outer layers of the
skin. However, there are many products and formulations
available (lotions, creams, gels and ointments) that vary in
their consistency from ‘light’ to ‘heavy’. Despite claims
from the manufacturers, evidence that any one is better
than another is weak.
Two recent systematic reviews have highlighted a
paucity of research to help guide clinicians and patients
in their choice.3 4 In summary, the ﬁeld is characterised
by a lack of good quality, randomised controlled trials
(RCTs) directly comparing commonly used emollients,
with medium-term to long-term data on clinically rele-
vant outcomes. While undertaking this research repre-
sents unique challenges, such as the range of possible
emollients to compare and the inability to mask users to
emollients of very different consistencies (eg, lotion vs
ointment), patients and clinicians have highlighted it as
an important issue. In the recent James Lind Alliance
eczema treatment research priority setting partnership,
‘Which emollients are the most effective and safe in
treating eczema?’ emerged as one of the highest ranked
uncertainties for further research.5
In order to address this uncertainty, we wanted to
undertake an RCT of commonly prescribed emollients
for the treatment of childhood eczema in primary care.
However, the feasibility of being able to conduct such a
trial was questionable, because of key issues such as
whether parents/carers would be willing to be assigned
and use a randomly allocated emollient for several
months, and uncertainty about optimal methods of
recruitment and data collection. Therefore, we con-
ducted a trial to determine the feasibility of recruiting,
retaining and collecting outcome data on young chil-
dren with eczema in a primary care setting, to inform
the design of a full trial.
METHODS
Design, participants and interventions
Full details can be found in the protocol paper.6 In
brief, COMET was a feasibility study of a pragmatic,
observer-blinded, RCT to compare the clinical and cost-
effectiveness of ‘leave on’ emollients in the treatment of
children with eczema. Throughout this paper, we will
use the term ‘parent’ to denote all carers/guardians
with parental responsibility.
Between July 2014 and April 2015, participants were
recruited in primary care (general practice) via two
pathways: ‘self-referral’ (usually in response to a letter
sent by their practice inviting them to take part) or
‘inconsultation’ (an approach during a surgery visit by
GP/practice nurse (PN), who also received consent and
undertook randomisation). GPs/PNs were asked to
record all approaches to potentially eligible participants
on a ‘recruitment log’. At the end of the study practices
also undertook searches to identify the number of
potentially eligible children who had at least one contact
with the practice during the recruitment period.
To be eligible, children had to have eczema, be aged
1 month to under 5 years and not be known to be sensi-
tive or allergic to any of the study emollients or their con-
stituents. Participants were randomly allocated by a
web-based system (1:1:1:1 ratio) to one of four emollients
(Aveeno lotion 400 mL, Diprobase cream 500 g,
Doublebase gel 500 g, Hydromol ointment 500 g) to use
as their leave-on emollient with the directions to ‘Use
twice daily and when required’. Study emollients were
prescribed for the duration of the study by participants’
GP surgeries and issued by pharmacies, as per usual care.
The trial manager telephoned participants 1 week after
randomisation to ensure that the allocated treatment had
been received and started. All other care (appointments,
prescriptions, referrals) was as per usual care. Research
team members (‘observers’) undertaking the baseline
and follow-up visits (but not clinicians, parents or partici-
pants) were blinded to emollient allocation.
Three key changes to the original protocol were
implemented in the ﬁnal 4 months of recruitment. First,
the diagnostic criterion was relaxed from ‘doctor diag-
nosis of eczema’ to ‘diagnosed by a doctor or an appro-
priately qualiﬁed health care professional with oversight
from a medically qualiﬁed doctor’. Second, the upper
age limit was raised from under 3 years to under 5 years
of age. Third, the number of practices was increased
from 16 to 22. These additional practices were only
asked to do the mail-out, not use the inconsultation
recruitment pathway as well.
Outcomes
Participants were followed-up for 12 weeks (84 days).
During this time, study visits were scheduled to take
place 28, 56 and 84 days after baseline and parents were
asked to complete a daily diary (paper and electronic
‘app’ versions were offered). In addition, the primary
care electronic medical records (EMR) were reviewed
for the 3 months participants were in the study.
Data were collected on:
▸ use of study emollient and other eczema treatments
(daily parent reported);
▸ eczema severity: weekly parent reported (Patient-
Oriented Eczema Measure, POEM;7 parent global
assessment) and monthly observer completed
(Eczema Area Severity Index, EASI;8 Six Area, Six
Sign Atopic Dermatitis, SASSAD;9 Three-Item
Severity, TIS10) assessments;
▸ quality of life: Atopic Dermatitis Quality of Life
(ADQoL)11 and Dermatitis Family Impact (DFI)12
(both monthly parent reported);
▸ skin hydration using a corneometer (see below)
(monthly observer collected);
▸ eczema-related prescriptions and healthcare resource
use (weekly parent reported and EMR review);
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▸ eczema-related personal costs, parent time off work
and child time away from school/day care (weekly
parent reported).
Parents who withdrew from the study at any point
were asked to complete a withdrawal questionnaire. At
the end of the study, parents were asked to complete an
exit questionnaire which included questions about their
experience of taking part in the study.
The primary outcome of this feasibility study was the
proportion of parents who reported use of the allocated
study emollient every day for the duration of follow-up
(12 weeks). Secondary outcomes were participant
recruitment and retention, data collection and com-
pleteness (including health economic), and the extent
to which the observers were kept blinded to the inter-
vention. Outcome data itself and other feedback will be
presented elsewhere.
Corneometry
Skin hydration was measured at two sites on the body
(antecubital fossa and forearm) using a corneometer
(Corneometer CM825, Courage & Khazaka electronic
GmbH, Cologne, Germany), in arbitrary units of 0–100,
with a higher measurement representing greater hydra-
tion. Presented measurements were adjusted for
ambient temperature and humidity, to give the predic-
tion of what each measurement would have been had it
been taken in the average conditions seen in the study;
22°C and 48.6% relative humidity. This adjustment was
based on an equation estimated by regressing the cor-
neometry measurements taken in the study on the corre-
sponding temperature and humidity readings (see
online supplementary appendix).
Sample size
Since this was a feasibility study, a formal sample size cal-
culation was not required. We aimed for a target sample
size of 160 participants. With this number, a true
consent rate of 50% (160 children participating having
invited 320 potentially eligible children) would be esti-
mated with 95% CI of the order 44–56%.
Analysis
We conducted linear or logistic regression (as appropri-
ate) to compare the characteristics of participants
recruited via the two recruitment pathways and those
who withdrew/stayed in the study. Observer blinding was
assessed using the Bang blinding index,13 which takes a
value between −1 and +1: +1 indicates complete lack of
blinding and 0 is consistent with perfect blinding.
Negative values indicate the respondent is wrong more
often than would be expected by chance, which can
arise, for example, if all participants are said to be on
one particular treatment irrespective of what they
receive.
Healthcare resource use and prescribed medications
were costed using relevant unit costs14–17 valued in
pound sterling and at 2014 prices. The cost of the
intervention emollients was estimated using three alter-
native methods; ﬁrst, via the prescription cost analysis
(PCA),15 second using the British National Formulary
(BNF)18 and third using the Drug Tariff (DT)19 and
Dictionary of Medicines and Devices (DMD).20 The
ﬁnal method aimed to estimate the true cost to the NHS
of prescribed medications by estimating the amount
community pharmacists are reimbursed for dispensing
prescriptions. This method incorporates a deduction for
any discount the pharmacy may have received, dispens-
ing fees and payments for containers, consumables or
other associated costs.
Health state utility values were estimated at each time
point using scores from the ADQoL.11 QALYs were
derived using the area under the curve approach21 and
by multiplying to an annual equivalent.
Ethics
The study was approved by Central Bristol Research
Ethics Committee (REC reference: 13/SW/0297),
Clinical Trial Authorisation given by the Medicines and
Healthcare products Regulatory Agency (MHRA refer-
ence: 03299/0017/001-003) and research governance
approvals obtained across all areas prior to the start of
recruitment. Written informed consent was received
from all participants.
RESULTS
Recruitment of participants
Between July 2014 and May 2015, 197 children were
recruited via 22 practices. The ﬂow of the participants
through the trial is shown in the CONSORT diagram
(ﬁgure 1), which distinguishes between the two recruit-
ment pathways.
Recruitment by self-referral pathway: 2026 potentially
eligible children were screened and GPs excluded 9%
(177/2026), the most common reason being ‘no longer
has eczema’ (37%, 66/177). Of the 1849 invitation
letters sent, responses were received from 20% (374/
1849) with 66% (246/374) declining to take part. Again,
the most common reason for not taking part was the
child having either no or only mild eczema (62%, 152/
246). A further 4 children were recruited by
word-of-mouth or after seeing a study poster/being
given a study ﬂyer, giving a total of 132 potentially eli-
gible participants who were screened by the research
team. Of these, 19% (25/132) were not recruited,
mainly because the carer could not be contacted (12/
25, 48%).
Recruitment by inconsultation pathway: Retrospective
searches identiﬁed 2552 potentially eligible children
who had at least 1 contact with their practice, and there-
fore could have been approached via this pathway.
Recording of these contacts by clinicians was poor, with
only 6 practices returning ‘recruitment logs’, which
detailed 66 encounters. Of these, the most common
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reasons given for not recruiting were that clinicians
either forgot to ask or were too busy (47%, 31/66).
The majority of participants (62%, 54/87) recruited
during the ﬁrst 6 months came via the self-referral
pathway (see online supplementary ﬁgure S1). However,
during the ﬁnal 4 months of recruitment, the number
of inconsultation referrals increased so that by the end
of the study, 90 (46%) of the total 197 participants came
via this route. Practices 1–16 sent reminder letters to
families who did not respond to the initial invitation and
still met the eligibility criteria, which resulted in the
recruitment of four additional participants.
Characteristics of participants
The mean age (SD) of participants at baseline was
21.7 months (12.8), with 85 (43%) female, 155 (85%)
Figure 1 CONSORT diagram—recruitment by referral pathway’ with accompanying text: aData from 13 general practitioner (GP)
practices (8 practices had no exclusions, 1 practice had 3 exclusions with no reasons given); bdata from 6 GP practices whose
GPs returned recruitment logs; cone participant withdrew after visit 3 from the inconsultation pathway.
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white and a mean Index of Multiple Deprivation (IMD)
score (SD) of 21.8 (14.2) (generated from participant
postcode). The mean (SD) eczema severity scores were
as follows: POEM 8.8 (5.9), EASI 2.9 (3.8), SASSAD 8.8
(8.4) and TIS 2.0 (1.7). The mean (SD) DFI and
ADQoL were 3.6 (4.8) and 0.787 (0.084), respectively.
However, as can be seen from table 1, participants
recruited inconsultation were younger (mean age in
months 17.0 vs 25.7, p<0.031), and had higher mean
POEM (10.3 vs 7.6, p=0.012) scores than those who were
recruited via self-referral.
Participant retention
Twenty-eight (14%) participants withdrew from the
study and 151 (77%) attended the ﬁnal follow-up visit.
Most participants who withdrew were recruited inconsul-
tation (21/90, 23%, compared with 7/107, 7%, of self-
referrals), including ﬁve children who did not attend
their baseline visit. All bar one participant (who was
recruited inconsultation) returned a withdrawal
questionnaire, and the most commonly cited reason for
withdrawing was lack of time (table 2).
Collection and completeness of outcome data
Twenty-two of 185 (12%) parents started using the app
version of the daily diary, but only 11 people used it for
the duration of the study. Technical problems meant
that it was not promoted after the ﬁrst 3 months of
recruitment. Of 150 parents completing an exit ques-
tionnaire, 121 (81%) said they liked the daily diary, 22
(15%) said they were not sure and 7 (5%) disliked it.
Table 3 shows that completeness of daily, weekly and
monthly data collected via the parent diary was generally
good. However, completion rates for individual sections
varied from 70% to 95% among those who returned the
diaries and from 57% to 78% of all participants. The
most poorly completed sections were daily record of
eczema treatment use and weekly time off school and
work. Owing to the cumulative nature of healthcare
costs, complete costing of healthcare resources was pos-
sible for only 62% (122/197) of participants, despite the
Table 1 Characteristics of participants at baseline by referral pathway
Self-referral (N=107)
Inconsultation
(N=90) p Value
n n
Mean age in months (SD) 25.7 (11.6) 107 17.0 (12.6) 90 0.031*
Number female (%) 46 (43%) 107 39 (43%) 90 0.868†
Number white (%) 98 (93%) 108 57 (74%) 77 0.088†
Mean IMD score (SD) 15.7 (10.5) 104 25.4 (13.8) 88 0.201*
Mean eczema severity scores (SD)
POEM (min 0, max 28, high=worse) 7.6 (5.7) 107 10.3 (5.8) 89 0.012*
EASI (min 0, max 72, high=worse) 2.8 (4.1) 105 3.1 (3.4) 79 0.841*
SASSAD (min 0, max 108, high=worse) 9.0 (8.7) 107 8.5 (7.9) 79 0.918*
TIS (min 0, max 9, high=worse) 2.1 (1.9) 107 2.0 (1.5) 79 0.571*
Skin hydration‡ (high=better)
Forearm 31.3 (11.8) 98 32.9 (10.1) 70 0.719*
Antecubital fossa 36.5 (14.8) 98 39.5 (12.6) 71 0.325*
Mean DFI score (SD) (min 0, max 30, high=worse) 2.9 (4.0) 107 4.6 (5.6) 79 0.224*
Mean ADQoL (SD) (min 0.356, max 0.841, high=better) 0.799 (0.065) 105 0.770 (0.103) 75 0.239*
*Linear regression model adjusting for GP practice.
†Logistic regression model adjusting for GP practice.
‡Measurements adjusted to average study conditions of temperature (22°c) and humidity (48.6%) (model described in the Methods section/
online supplementary appendix). Data presented in arbitrary units ((min 0, max 100, high=more hydrated).
Table 2 Reasons for participant withdrawal by recruitment pathway
Reasons for withdrawal*
Recruitment pathway
Self-referral (n=7) Inconsultation (n=21)
Study emollient not working/effective 0 2
Adverse reaction to study emollient 2 0
Disliked emollient given 0 2
Just simply changed my mind 0 2
Do not have enough time 4 10
My child’s skin has improved—no longer need emollient 0 4
Other 2 7
*More than one reason could be cited.
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relevant section of each diary having been completed by
at least 70% (138/197).
Completeness of data collected by the observers was
also good, with the median number (IQR) of visits with
complete data (maximum 4) for EASI, TIS and
SASSSAD all being 4.0 (3.0 to 4.0). The completeness
for corneometry was lower and differed by site (forearm
3.0 (2.0–4.0), antecubital fossa 4.0 (2.0–4.0)), as it was
not possible to use the one available corneometer at
concurrent follow-up visits. A greater proportion of
observer visits occurred ±10 days than ±5 days of the
scheduled date, and baseline visits were more likely to
be timely for participants who self-referred (see online
supplementary table S1).
The Bang blinding indices for observer unblinding to
the different emollients are shown in table 4 (observer
guess and treatment assignment for each assessment, by
which this index was calculated, are shown in online
supplementary tables S2–S5). Observers reported not
knowing which study emollient the participants were
using at most visits. They correctly identiﬁed the study
emollient in eight participants at the baseline and ﬁrst
follow-up visits. The most common reasons given for
unblinding were the parent telling them (6/8 baseline
and 6/8 visit 1) or the observer seeing the study emolli-
ent during the visit (2/8 baseline and 1/8 visit 1).
Adherence to intervention
Of the 197 participants, parents of 20 (10%) reported
using their allocated emollient daily for 84 days
(primary outcome). However, 38 (19%) did not give any
data on study emollient use. Therefore, of the 159
parents of participants who completed this question at
least once, 49 (31%) said they used the study emollient
on each occasion that they completed the question.
The majority (156/162, 96%) of parents reported
some use of a non-study emollient: 25% (41/162)
reported use every day (that data were provided) and
51% (82/162) reported using an ‘other’ emollient on
up to 50% of days. Fifty-three per cent (85/159) of
parents reported using an ‘other’ emollient instead of
the study emollient at least once. Of these 85 parents,
86% (73/85) used an ‘other’ emollient rather than the
study emollient half of the time.
Analysis of the EMRs revealed that while the mean
(SD) number of intervention emollient prescriptions
was 1.44 (0.78), the number of eczema-related prescrip-
tions for non-intervention emollients was 1.28 (2.13).
This included a mean (SD) number of 0.48 (0.99) non-
study emollients, 0.43 (0.93) topical corticosteroid and
0.31 (0.69) bath/shower product prescriptions.
Economic evaluation
The main cost driver as recorded in the EMRs was GP
appointments with a mean cost of £11.77 over the
follow-up period (see online supplementary table S6).
On average, the cost of eczema-related prescribed medi-
cations excluding trial emollients equated to £6.97.
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Healthcare and intervention emollient costs did not
appear to differ considerably between treatment arms
(table 5). The mean (SD) cost to the NHS of each of the
trial emollients using the DT and DMD was £11 (£5), £9
(£5), £9 (£5) and £8 (£5), for Aveeno lotion, Diprobase
cream, Doublebase gel and Hydromol ointment, respect-
ively. Emollient costs were slightly higher using this
method in comparison to the PCA or BNF (table 5).
Complete ADQoL data for 119 participants allowed esti-
mation of mean (SD) annual QALYs of 0.799 (0.061).
Parents reported additional expenditure due to their
child’s eczema on items including: eczema treatments
(n=25), clothes (n=14), household items (n=12), toilet-
ries (n=11) and food and drink (n=9). Time off paid
employment or school/day care was reported infre-
quently: over the entire follow-up period, only 3 days off
paid employment and 2 days off school/day care were
reported across all participants.
DISCUSSION
This is the ﬁrst study to show that it is feasible in a
primary care setting to recruit and randomise young
children with eczema to ‘leave-on’ emollients and follow
them up, keeping observers blinded to their allocation.
We exceeded our recruitment target, although in the
ﬁnal 4 months, we enlisted the help of six more prac-
tices than originally planned and relaxed the age and
diagnostic eligibility criteria. Reported daily use of the
study emollients was low, however, and the use of other
emollients was common.
We conducted a well-executed, pragmatic trial over-
coming many practical and logistical challenges,
meeting regulatory requirements of a Controlled Trial of
an Investigational Medicinal Product (CTIMP). More
detail on trial conduct can be found in the published
trial protocol6 and we report the ﬁndings in accordance
with the CONSORT guidelines.22 These ﬁndings have
implications for future trials of emollients and other
treatments for children with eczema, but also for trials
of treatments of other long-term conditions in primary
care with medium-term follow-up.
A strength of this study is its exploration of the two
possible recruitment pathways and their feasibility in a
main trial. By asking most practices to try and recruit via
the two routes, we now have a strong understanding of
the number (and characteristics) of children likely to be
recruited in a deﬁnitive trial, and the proportion likely
to withdraw (and reasons why). While having the two
pathways into the study helped the trial meet its recruit-
ment target, we are mindful that the characteristics of
participants, and their commitment to staying in the
trial differed for participants recruited via these two
routes. Of 90 participants recruited via the inconsulta-
tion pathway, 21 (23%) withdrew and 53 (59%) attended
their ﬁnal appointment, compared with 7 (7%) and 98
(92%), respectively, for participants recruited via self-
referral (most mail-out). With respect to the mail-out
invitation, the high number of children identiﬁed with
mild or no eczema reﬂects the fact that for many, their
diagnosis will be historical and for others, erroneous.
One way to improve this may be to limit invitations to
children with a recent relevant prescription (suggesting
‘active’ disease), as per the BATHE study.23 The rise in
the rate of children recruited inconsultation may reﬂect
both the staggered nature in which the practices came
into the study but also a learning and conﬁdence effect
among recruiting clinicians. Although all practices were
members of the Clinical Research Network, they had
variable levels of experience in recruiting to studies of
this type and each study has its unique processes that
have to be followed.
In addition to investigating recruitment and retention,
we have also collected important adherence, outcome
(including corneometry) and health economic data. We
found that it is feasible to collect and cost the data
required to perform an economic evaluation in this
setting. EMR records provided a rich source of complete
healthcare resource use data, indicating that in further
studies, healthcare resource use collected from diaries
could be reduced. Given that time away from paid
employment and school were very rarely reported, cap-
turing these data in a future trial would likely be less
important. Our assessment of additional items bought
due to eczema has highlighted a list of important cat-
egories to include in future studies. At inception, no
generic measure of health-related quality of life that was
psychometrically and conceptually robust enough for
young children under the age of 3 was available. For this
reason, we used the ADQoL, from which we were able to
estimate QALYs. However, given that this is a condition-
speciﬁc preference-based measure, the results may not
be comparable across conditions.
Table 4 Bang blinding index with 95% two-sided CI (comparing correct treatment response with incorrect treatment or do
not know response)
Study emollient
Visit
Baseline 1 2 3
Aveeno lotion 0.2 (0.0, 0.4) 0.0 (0.0, 0.1) CE CE
Hydromol ointment 0.1 (−0.1, 0.2) 0.0 (−0.1, 0.1) CE CE
Diprobase cream 0.1 (0.0, 0.2) 0.1 (0.0, 0.2) CE CE
Doublebase gel 0.1 (0.0, 0.2) 0.0 (−0.1, 0.0) CE CE
CE, cannot be estimated due to lack of data (see online supplementary tables S2–S5).
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Reported use of study emollients was low and use of
other emollients either alongside or instead of the allo-
cated treatment common, but our ability to interpret
these ﬁndings is limited by missing data. While comple-
tion of the daily diary was generally good, questions on
the use of eczema treatments (including study emolli-
ent) were the most poorly completed. We think this is
because parents left an item blank when a treatment was
not used, rather than recording ‘None’ or ‘0’, meaning
it was classed as ‘missing’. For example, if missing data
on ‘other’ emollient use are treated as ‘no use’ on those
days for which complete data are available on the use of
the study emollient, then only 6% (10/162) (compared
with 25%) of parents of participants used a non-study
emollient every day and 71% of parents of participants
(115/162) (compared with 51%) reported using
another emollient on up to 50% of days. Another limita-
tion in the data on emollient use is that we are unable
to distinguish between use as leave-on therapy (in the
same way as the study emollients) and use as soap substi-
tute. Missing data would have been less of a problem
had the ‘app’ version of the diary worked better and
been used by more parents—one of the attractions of
collecting data from parents this way is the ability to
automatically monitor data entry in real time and
prompt parents to answer all the questions.
Although initial interest among parents in using our
‘app’ was high, its development and incorporation in
this study was challenging because: (1) regulatory
requirements for CTIMPs meant, additional and time-
consuming testing to ensure that data were transmitted
securely; and (2) the cost required to develop a fully
functional app for the most common smart phone and
tablet platforms (iOS and Android). Therefore, while
we cannot conclude that studies similar to ours should
not consider data collection via bespoke apps, we
would certainly caution against underestimating the
time, cost and technical implications of doing this. In
future studies, automatic email prompts to parents to
complete online questionnaires are probably a safer
and more cost-effective way of maximising data collec-
tion. For parents who would still prefer paper question-
naires, clear instructions should be given about the
importance of positively indicating ‘no treatment use’
(as opposed to leaving an answer blank). We also rec-
ommend that future studies involving young children
should be realistic about parents’ ability to adhere to
strict follow-up schedules, with study protocols provid-
ing realistic ‘windows’ (eg, ±10 days if permissible)
within which to expect data collection; and where it is
desirable to keep the observer blinded, giving unam-
biguous instructions to parents to avoid accidental
disclosure.
For future trials comparing emollients, researchers
should be encouraged that participants who consent to
taking part generally stay in the trial, although they may
wish to recruit participants using just the self-referral
pathway. Researchers also need to be aware that couse of
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emollients appears to be common, and the extent to
which this matters will depend on where future studies
sit on the efﬁcacy–effectiveness spectrum. Whatever the
design, this study provides the foundations for future
deﬁnitive studies to answer the prioritised research ques-
tion ‘Which emollient is the most effective and safe in
treating eczema?’5
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